Skip to main content

Table 2 Types of infections, pathogens and dosage of 67 patients with high-dose daptomycin therapy

From: Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients

Characteristica Total (n = 67) Daptomycin dose (mg/kg)  
≤ 8 (n = 41) > 8 (n = 26) P value
Pathogen     
MSSA 6 (9.0%) 4 (9.8%) 2 (7.7%) 0.77
MRSA 38 (56.7%) 23 (56.1%) 15 (57.7%) 0.90
Vancomycin MIC ≥ 2 μg/mL 24 (35.8%) 14 (34.1%) 10 (38.5%) 0.80
MRCoNS 10 (14.9%) 6 (14.6%) 4 (15.4%) 0.93
VRE 18 (26.9%) 12 (29.3%) 6 (23.1%) 0.58
Type of infection     
Community-onset 18 (26.9%) 10 (24.4%) 8 (30.8%) 0.57
All bacteremia 54 (80.6%) 32 (78.0%) 22 (84.6%) 0.75
Primary bacteremia 10 (14.9%) 7 (17.1%) 3 (11.5%) 0.54
Endocarditis 11 (16.4%) 3 (7.3%) 8 (30.8%) 0.03
Catheter-related bacteremia 16 (23.9%) 11 (26.8%) 5 (19.2%) 0.48
cSSTI 16 (23.9%) 9 (22%) 7 (26.9%) 0.64
Bone & joint infection 9 (13.4%) 6 (14.6%) 3 (11.5%) 0.72
Otherb 5 (7.46%) 5 (12.2%) 0 (0%) 0.15
Duration of therapy, days 14 (3–53) 13 (3–53) 14.5 (3–42) 0.47
Mean doses (mg/kg) 7.90 6.98 9.36  
  1. a Data are median (range) for continuous variables.
  2. b Including urinary tract infections (n = 3) and intra-abdominal infections (n = 2).
  3. cSSTI, complicated skin and soft-tissue infection; MIC, minimum inhibitory concentration; MRCoNS, methicillin-resistant coagulase-negative staphylococci; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; VRE, vancomycin-resistant enterococci.